EIM
STML

Essex Investment Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Essex Investment Management’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-18,600
Closed -$365K – 385
2013
Q4 		$365K Sell
18,600
-1,132
-6% -$30.2K 0.05% 296
2013
Q3 		$894K Buy
19,732
+2,515
+15% +$82K 0.14% 189
2013
Q2 		$410K Buy
+17,217
New +$274K 0.07% 235

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Essex Investment Management's STML Position: Q1 2014 in Review

Essex Investment Management sold out of Stemline Therapeutics, Inc. (STML) in Q1 2014, closing a stake of 18,600 shares — an estimated $365K sold.

Essex Investment Management first reported a position in STML in Q2 2013 and held it in 3 quarters. The position peaked at $894K in Q3 2013. 61 funds tracked by Wall St. Rank hold STML as of Q1 2014.

  • Essex Investment Management reported no remaining Stemline Therapeutics, Inc. position as of Q1 2014 after selling out during the quarter.
  • Essex Investment Management sold 18,600 Stemline Therapeutics, Inc. shares in Q1 2014, an estimated $365K.
  • Essex Investment Management first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 3 quarters.
  • Essex Investment Management's Stemline Therapeutics, Inc. position peaked at $894K in Q3 2013.
  • 61 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2014.

Based on Essex Investment Management's 13F filing for Q1 2014, filed 28 Apr 2014.